Trials / No Longer Available
No Longer AvailableNCT03138629
Expanded Access to VAL-083
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Kintara Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VAL-083 | VAL-083 will be administered intravenously |
Timeline
- First posted
- 2017-05-03
- Last updated
- 2023-11-22
Source: ClinicalTrials.gov record NCT03138629. Inclusion in this directory is not an endorsement.